International Journal of Clinical Pharmacology, Therapy and Toxicology 1990-08-01

Pharmacokinetics of triflusal after single and repeated doses in man.

J Ramis, J Torrent, R Mis, L Conte, M J Barbanoj, J Jané, J Forn

Index: Int. J. Clin. Pharmacol. Ther. Toxicol. 28(8) , 344-9, (1990)

Full Text: HTML

Abstract

Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship between plasma levels and dosage patterns. Plasma concentrations of triflusal and its main metabolite, 2-hydroxi-4-trifluoromethylbenzoic acid (HTB), were determined by HPLC. Triflusal (t1/2 = 29-35 min) metabolized rapidly into HTB. Four h after the first or last repeated dose administration, triflusal levels could not be detected. After the administration of 300 mg every 8 h, the parameters obtained for HTB were: Cmax-ss = 178 +/- 42 micrograms/ml, tmax-ss = 1.9 +/- 0.7 h, Cmin-ss = 155.6 +/- 41.2 micrograms/ml, Cavg-ss = 168.0 +/- 41.8 micrograms/ml and a t1/2 of 48 +/- 15 h. The parameters obtained for the dosage of 600 mg every 24 h were: Cmax-ss = 153 +/- 40 micrograms/ml, tmax-ss = 2.7 +/- 0.9 h, and a t1/2 of 50 +/- 16 h. No significant differences were observed between the elimination half-life obtained after the single dose and after the two repeated dose regimens studied. This finding suggests that HTB displays a linear pharmacokinetic behaviour.


Related Compounds

  • 4-Trifluoromethyls...

Related Articles:

The study of the influence of surfactant charge on alkaline hydrolysis reactions of acetylsalicylic acid (ASA) and triflusal (TFL) using spectrophotometric methods.

2007-07-01

[Eur. J. Pharm. Sci. 31(3-4) , 211-20, (2007)]

A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.

2011-12-01

[Expert Opin. Drug Metab. Toxicol. 7(12) , 1471-9, (2011)]

Salicylates increase insulin secretion in healthy obese subjects.

2008-07-01

[J. Clin. Endocrinol. Metab. 93(7) , 2523-30, (2008)]

Protective effects of triflusal on secondary thrombus growth and vascular cyclooxygenase-2.

2008-08-01

[J. Thromb. Haemost. 6(8) , 1385-92, (2008)]

Photonucleophilic addition of the epsilon-amino group of lysine to a triflusal metabolite as a mechanistic key to photoallergy mediated by the parent drug.

2009-07-01

[ChemMedChem 4(7) , 1196-202, (2009)]

More Articles...